Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
ROCKET PHARMACEUTICALS, INC. executive Martin Wilson, General Counsel, reported a sale of 3,493 shares of common stock on 2026-08-13 at $3.381 per share. The sale was made to cover tax withholding obligations arising from the vesting of Restricted Stock Units, and Wilson now holds 674,484 shares directly, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. Chief Operating Officer Christopher James Stevens reported selling 36,658 shares of common stock on 2026-08-11 at $3.499 per share. According to the company’s disclosure, these shares were sold to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs). Following this tax-related sale, Stevens directly holds 505,784 shares of common stock, including RSUs that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. executive Sarbani Chaudhuri sold 4,701 shares of common stock on August 11, 2026, at $3.499 per share. The filing states the shares were sold to pay tax withholding obligations related to vesting RSUs. After this transaction, Chaudhuri directly held 262,809 shares, including Restricted Stock Units that convert to common stock on a one-for-one basis.
RCKT reporting person Martin Wilson filed a notice of proposed sale of common stock. The filing lists up to 3,493 common shares to be sold through Fidelity Brokerage Services LLC on or after 08/13/2026, following a restricted stock vesting event for 3,493 shares on 08/11/2026 as compensation. It also discloses prior sales of 3,361 shares for $12,118.42 on 05/13/2026 and 662 shares for $1,995.53 on 05/19/2026.
Gaurav Shah filed to sell 2,837 shares of common stock of the issuer of RCKT through Fidelity Brokerage Services LLC on August 13, 2026, listed on NASDAQ, with an indicated value of $9,592.18. The shares relate to restricted stock vesting designated as compensation.
Over the prior three months, Shah reported sales of 2,728 shares for $9,836.08 on May 13, 2026, 2,409 shares for $7,261.69 on May 19, 2026, and 55,684 shares for $171,818.55 on May 21, 2026.
Rocket Pharmaceuticals, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by U.S. FDA approval of KRESLADI™ and monetization of the associated Priority Review Voucher. Second-quarter net income was $123.2 million, compared with a net loss of $68.9 million a year earlier, helped by a $178.2 million gain from the sale of the voucher. Operating expenses declined to $46.9 million from $71.1 million, reflecting lower research and development and general and administrative costs following a prior restructuring.
For the first six months of 2026, Rocket reported net income of $75.6 million versus a net loss of $130.3 million in the prior-year period. Cash, cash equivalents and investments increased to $283.7 million as of June 30, 2026, from $188.9 million at year-end 2025, and the company expects its cash runway to extend into the second quarter of 2028. Rocket highlighted completion of safety observation for the first three Danon disease patients in its modified pivotal Phase 2 trial, continued FDA interactions on the path to rapidly completing this trial, and multiple planned second-half 2026 milestones across its cardiovascular gene therapy programs, including PKP2-ACM and BAG3-DCM, alongside commercial preparations for KRESLADI.
Rocket Pharmaceuticals, Inc. reported a sharp swing to profitability for the quarter ended June 30, 2026, driven by monetizing its Rare Pediatric Disease Priority Review Voucher. Net income was $123.2 million versus a net loss of $68.9 million a year earlier, primarily reflecting a $178.2 million gain on the PRV sale for $180 million.
Operating performance remained loss-making but more efficient. For the quarter, research and development expense fell to $29.5 million from $42.7 million, and general and administrative expense declined to $17.4 million from $25.0 million, with no new restructuring charges. Six‑month net income was $75.6 million versus a $130.3 million loss in 2025.
Liquidity improved significantly: cash, cash equivalents and investments totaled $283.7 million at June 30, 2026, up from $188.9 million at year‑end 2025, supporting management’s view that existing resources can fund operations into the second quarter of 2028. KRESLADI™ received FDA accelerated approval in March 2026, but the company has not yet generated product revenue and continues to invest in launch activities and its cardiovascular genetic medicines pipeline. The company also disclosed ongoing shareholder and derivative litigation related to prior Danon disease trial communications.
Rocket Pharmaceuticals’ Chief Operating Officer Christopher James Stevens received equity compensation on August 3, 2026, consisting of 101,428 stock options at an exercise price of $3.41 expiring August 3, 2036, and 73,313 RSUs. Both awards vest one-third on August 3, 2027, with the remaining portions vesting in equal quarterly installments over the following two years. After these grants, he directly holds 542,442 shares of common stock, including RSUs, plus the option to purchase 101,428 shares.